Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Ginkgo Bioworks HoldingsMEX:DNA 54 Quick Ratio is 5.15 as of Mar. 2026, which is 13% below its 10-year median of 5.95. GuruFocus rates MEX:DNA with a GF Score™ of 54/100 and a GF Value™ of MXN149.41 (Modestly Undervalued). The stock has 5 warning signs investors should review. Among 1,411 Biotechnology companies, Ginkgo Bioworks Holdings ranks better than 61.23% on this metric.
Ginkgo Bioworks Holdings (MEX:DNA) Quick Ratio Explanation
The quick ratio is more conservative than the Current Ratio because it excludes inventories from current assets. The ratio derives its name presumably from the fact that assets such as cash and marketable securities are quick sources of cash. Inventories generally take time to be converted into cash, and if they have to be sold quickly, the company may have to accept a lower price than book value of these inventories. As a result, they are justifiably excluded from assets that are ready sources of immediate cash.
In general, low or decreasing quick ratios generally suggest that a company is over-leveraged, struggling to maintain or grow sales, paying bills too quickly or collecting receivables too slowly. On the other hand, a high or increasing quick ratio generally indicates that a company is experiencing solid top-line growth, quickly converting receivables into cash, and easily able to cover its financial obligations. Such companies often have faster inventory turnover and cash conversion cycles.
The higher the quick ratio, the better the company's liquidity position.
Ginkgo Bioworks Holdings Quick Ratio Related Terms
Ginkgo Bioworks Holdings Quick Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MEX:DNA vs RZLT, EIKN, ARTV: Quick Ratio Comparison
For the Biotechnology subindustry, Ginkgo Bioworks Holdings's Quick Ratio, along with its competitors' market caps and Quick Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Ginkgo Bioworks Holdings Quick Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Ginkgo Bioworks Holdings's Quick Ratio distribution charts can be found below:
* The bar in red indicates where Ginkgo Bioworks Holdings's Quick Ratio falls into.
The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. For this reason, the ratio excludes inventories from current assets.
Ginkgo Bioworks Holdings's Quick Ratio for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Ginkgo Bioworks Holdings (MEX:DNA) has a Quick Ratio of 5.15 as of Mar. 2026. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on Ginkgo Bioworks Holdings and its competitors. This is 13% below median its historical median of 5.95. Over the past decade, Ginkgo Bioworks Holdings' Quick Ratio has ranged from 4.39 to 20.01. According to the industry distribution chart, Ginkgo Bioworks Holdings ranks #547 out of 1411 companies in the Biotechnology industry, placing it in the top 38.8%.
Is Ginkgo Bioworks Holdings' Quick Ratio too high?
Ginkgo Bioworks Holdings' current Quick Ratio of 5.15 is 13% below median its 10-year median of 5.95. Over the past 10 years, this metric has ranged from a low of 4.39 to a high of 20.01. The Biotechnology industry median Quick Ratio is 3.56. Ginkgo Bioworks Holdings' value of 5.15 is 44.7% above this industry median. Based on the distribution chart, Ginkgo Bioworks Holdings ranks #547 out of 1411 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Ginkgo Bioworks Holdings has a GF Score™ of 54/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Ginkgo Bioworks Holdings' Quick Ratio compare to RZLT and EIKN?
According to the Biotechnology industry distribution chart, Ginkgo Bioworks Holdings ranks #547 out of 1411 companies for Quick Ratio. This puts Ginkgo Bioworks Holdings in the upper half of its industry. The industry median Quick Ratio is 3.56. Ginkgo Bioworks Holdings' value of 5.15 is 44.7% above this benchmark. Historically, Ginkgo Bioworks Holdings' own Quick Ratio has ranged from 4.39 to 20.01 over the past decade. While the company's 10-year median is 5.95 vs. the industry median of 3.56, Ginkgo Bioworks Holdings has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Quick Ratio for a Biotechnology company?
The median Quick Ratio among Biotechnology companies is 3.56, based on 1,411 companies in the industry. Companies in the top quartile (top 25%) have a Quick Ratio significantly above this median, while those in the bottom quartile fall well below. However, Quick Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Ginkgo Bioworks Holdings's current Quick Ratio of 5.15 is 44.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Quick Ratio mean?
A high Quick Ratio can signal that a stock is expensive relative to its fundamentals. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on Ginkgo Bioworks Holdings and its competitors. For the Biotechnology industry, the median Quick Ratio is 3.56 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Ginkgo Bioworks Holdings's current Quick Ratio is 5.15, which is 13% below median its own 10-year median of 5.95. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ginkgo Bioworks Holdings stock overvalued right now?
Based on GuruFocus' analysis, Ginkgo Bioworks Holdings (MEX:DNA) is currently considered Modestly Undervalued. The stock's GF Value™ is MXN149.41, compared to a current price of MXN170.00 — trading 13.8% above its estimated fair value. The current Quick Ratio is 5.15, which is 13% below median its 10-year median of 5.95 and 44.7% above the Biotechnology industry median of 3.56. Ginkgo Bioworks Holdings' overall GF Score™ is 54/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Quick Ratio calculated?
Quick Ratio is calculated from a company's financial statements. For Ginkgo Bioworks Holdings (MEX:DNA), the current Quick Ratio is 5.15 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Ginkgo Bioworks Holdings (MEX:DNA) Overvalued in 2026?
Based on GuruFocus' analysis, Ginkgo Bioworks Holdings stock appears to be overvalued.
The current stock price of MXN170.00 is trading 13.8% above its estimated GF Value™ of MXN149.41.
GuruFocus considers Ginkgo Bioworks Holdings to be Modestly Undervalued.
Key valuation signals for MEX:DNA:
Quick Ratio: 5.15 (13% below median its 10-year median of 5.95)
GF Value™: MXN149.41 vs. price of MXN170.00 (13.8% above fair value)
Industry Position: 44.7% above the Biotechnology median (#547 of 1411)
No single metric tells the full story. See the MEX:DNA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Ginkgo Bioworks Holdings Inc is the platform for cell programming, providing flexible, end-to-end services that solve challenges for organizations across diverse markets, from food and agriculture to pharmaceuticals to industrial and specialty chemicals. The Company reorganized its operations into two operating and reportable segments: Cell Engineering engaged in providing biological R&D services for customers across a range of industries and Biosecurity that provides services to government and commercial customers to identify, monitor, prevent, mitigate, and ultimately protect humanity from biological threats. The maximum of revenue is from Cell Engineering Segment.
54GF Score
Get the complete analysis for MEX:DNA
Quick Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEX:DNA has been successfully added to your 
